Navigation Links
ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
Date:1/9/2009

ZURICH, Switzerland, Jan. 9/PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of the Phase I/IIa clinical development of its anti-TNF alpha antibody fragment ESBA105 in osteoarthritis (OA). This double-blind, randomized, placebo-controlled Phase I/IIa clinical study is designed to investigate the safety, tolerability and efficacy on pain with ESBA105 applied locally via intra-articular administration to patients with severely painful OA of the knee. The multicenter study is initiated at various sites across Switzerland.

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, commented, "As of today, no disease-modifying osteoarthritis drug exists, which is the key unmet need. OA is being increasingly recognized as driven by episodes of local inflammation and thus, TNF alpha represents a highly promising target. TNF alpha is excessively generated in OA by chondrocytes, which are located within the cartilage. Thus, to achieve disease-modifying activity, it is expected that the drug needs to penetrate into the cartilage, which cannot be achieved by the currently marketed TNF inhibitors. With ESBA105, we observe a very efficient penetration into the cartilage. By that, inhibiting TNF alpha can address the major aspects of OA therapy: signs and symptoms and cartilage degeneration. If clinically successful, ESBA105 is uniquely positioned to fill the need to treat OA with a safe and effective local therapy. A disease-modifying drug would revolutionize the treatment of this debilitating disease."

TNF alpha is a cytokine and a key player in inflammation, and has been identified as a major contributor to pain (signs and symptoms) and cartilage degeneration (structure modification), the main clinical characteristics of OA. Current treatments for OA comprise mainly of non-steroidal anti-inflammatory drugs and intra-articular injections of hyaluronic acids and cortico
'/>"/>

SOURCE ESBATech AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
2. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
3. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
4. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
5. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
6. Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
7. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
8. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
9. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
10. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
11. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... March 30, 2015  Orexigen Therapeutics, Inc. (Nasdaq: ... Cannell has joined as Chief Commercial Officer. ... Contrave® /Mysimba™ (naltrexone HCl / bupropion HCl extended ... global commercial strategy, assuming responsibilities previously held by ... commercial effort through the U.S. launch of Contrave, ...
(Date:3/30/2015)... 2015 NiQ Health, "the ... the high level interface capabilities of their CarePlus™ ... The partnership between CarePlus™ and ClinicAll ... allows patients to choose the most appropriate alarm ... The advanced functionality of CarePlus™ allows patient alarms ...
(Date:3/30/2015)... , March 30, 2015  Edison Nation Medical, ... worldwide search for product innovations to assist seniors ... ideas uncovered during the 8-week search will be ... commercialization.  Invention ideas can be submitted through a ... through May 28, 2015. The objective ...
Breaking Medicine Technology:Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 2Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 3Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 4Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 5Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 6Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 7Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 8Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 9Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 10NiQ Health Announces CarePlus(TM) Integration with ClinicAll 2Edison Nation Medical Announces Open Innovation Search Focused on Senior Mobility Products 2Edison Nation Medical Announces Open Innovation Search Focused on Senior Mobility Products 3
... BELL, Pa., Aug. 8, 2011 Inovio Pharmaceuticals, Inc. (NYSE AMEX: ... ended June 30, 2011. Total revenue was $2.4 million ... 2011, compared to $1.1 million and $2.5 million for the same ... and six months ended June 30, 2011, were $7.6 million and ...
... Aug. 5, 2011 Jury selection in the second trial ... begun in Clark County, Nevada. The Nevada Supreme Court lifted ... it was determined by the court that nurse David Hambrick, ... "does not possess the requisite skill, knowledge or experience to ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 9Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 10Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 11Second Trial in the Largest Hepatitis C Outbreak in U.S. Begins - Mainor Eglet Law Firm Files for Plaintiffs 2
(Date:3/30/2015)... On March 11, 2015, Elle Magazine, in an ... six new treatment options for dealing with stubborn, unwanted fat. ... topical product. The other three technologies use devices to deliver ... freezing cold ( CoolSculpting ) to kill fat cells. (see: ... us to permanently remove unwanted fat," says Dr. Simon Ourian, ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 A key ... neurological diseases plays an important role in the response ... scientists from the Icahn School of Medicine at Mount ... diseases have long been associated with inflammation, part of ... when immune cells home in to attack invaders like ...
(Date:3/30/2015)... Vancouver, BC (PRWEB) March 30, 2015 ... recently announced that the majority of cases taken up ... trial. This means that the lawyers help protect the ... through the tedious court process. The announcement comes across ... their primary job is to provide convenience to their ...
(Date:3/30/2015)... Jose, California (PRWEB) March 30, 2015 ... population and government efforts to develop and establish chronic ... management therapies. Growth in the market is poised to ... as a result of the increase in chronic health ... diseases, and rheumatoid arthritis, among others. While conventional treatment ...
(Date:3/30/2015)... March 30, 2015 On March 19th, ... Field, home of the Detroit Lions, LiveToBeSober.org hosted the ... recognized pastors, ministers and bishops as well as other ... the audience at the luncheon, including retired Detroit Lions ... Per Wickstrom and two survivors of their own personal ...
Breaking Medicine News(10 mins):Health News:UltraShape and CoolSculpting: Two New Fat-Busting Technologies 2Health News:Mount Sinai Scientists Establish Link Between Neurodegenerative Disease and the Body’s Response to Viral Infection 2Health News:Mount Sinai Scientists Establish Link Between Neurodegenerative Disease and the Body’s Response to Viral Infection 3Health News:Jiwa Law Corporation States That Majority of Their Cases Get Settled Before Trial 2Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:LiveToBeSober.org Releases Highlight Reel of Substance Abuse Conference Keynote Speakers 2
... researchers has constructed a model that predicts how an ... airliners. ,The study, "Modeling the Worldwide Spread ... in the January issue of the journal PLoS Medicine. ... world's largest-scale epidemic simulation of its kind. ...
... suggests that TEMPE, a topical anesthetic spray has the ... with premature ejaculation and might be useful// as a ... in the February issue of the urology journal BJU ... studied 54 men with premature ejaculation, randomly assigning them ...
... Rs.350 million to provide health insurance to around 1.2 ... H.D. Kumaraswamy announced// here Wednesday. ,"We are aware ... thousands of families. We have decided to provide health ... has been fixed for the project this year," Kumaraswamy ...
... that a novel needle-free vaccine approach// is effective and ... of Alzheimer’s disease. ,The transdermal, or ... of preventing or treating the devastating neurodegenerative disease with ... ,The study was published online this week in The ...
... effective procedure to combat obesity in adolescents,// according to a ... first study to evaluate the lap band in patients under ... average lost about 50% of their excess weight by one ... issue of the Journal of Pediatric Surgery. Currently, the lap ...
... Women with a history of abuse by intimate partners ... women with no history of such abuse, according to ... plan. ,The higher costs and utilization continued ... Group Health, the University of Washington (UW), and the ...
Cached Medicine News:Health News:Scientists Assess Risk of Flu Pandemic Spread Via Global Airlines 2Health News:Scientists Assess Risk of Flu Pandemic Spread Via Global Airlines 3Health News:TEMPE Spray Delays Ejaculation 2Health News:Karnataka's Free Health Insurance to the Poor 2Health News:Transdermal Vaccine Effective in Treating Alzheimer's Disease in Mice 2Health News:Stomach Banding Surgery Effective for Adolescents 2Health News:Stomach Banding Surgery Effective for Adolescents 3Health News:Health Care Costs - Significant for Abused Women 2
Subretinal Fluid Cannula, Straight; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip....
Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
...
Lacrimal Cannula, Curved - Open End, 21gSize: 21g x 1-1/2"....
Medicine Products: